PRODUCTS

1803573-19-4| (S)-5-fluoro-3-methylisobenzofuran-1(3H)-one is the key chiral intermediate of Lorlatinib (Lorlatinib, PF-06463922).

Pfizer's new generation ALK/ROS1 tyrosine kinase inhibitor Lorlatinib was granted breakthrough drug designation by the FDA. Currently, Lorlatinib's marketing application has been approved by the U.S., European and Japanese drug regulatory agencies.

Japan approved Pfizer Pharmaceuticals Co., Ltd.'s third-generation ALK inhibitor Lorlatinib (trade name LORBRENA) on September 21, 2018. It is suitable for progression or intolerance after treatment with ALK inhibitors, anaplastic lymphoma kinase (ALK) Treatment of patients with positive locally advanced or metastatic non-small cell lung cancer.

On November 2, 2018, the U.S. Food and Drug Administration announced the approval of Lorlatinib (Lorlatinib) for marketing. The trade name of Lorlatinib is "Lorbrena". For the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), it is suitable for patients whose disease has deteriorated after crizotinib treatment and who have used at least one other ALK inhibitor to treat metastatic disease, or take alectinib or Crizotinib is the first ALK inhibitor therapy for patients whose disease has worsened after metastatic disease. Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI).